Press release
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025.\n\n\nThe webcast can be accessed on the Investors section of the Company’s website at Kalvista.com. A replay will be available for at least 30 days following the event.\n\n\nAbout KalVista Pharmaceuticals, Inc.\n\n\nKalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250904776900/en/\n\nInvestors:\nRyan Baker\nHead, Investor Relations\n(617) 771-5001\[email protected]\n\n\nMedia:\nMolly Cameron\nDirector, Corporate Communications\n(857) 356-0164\[email protected]\n\n\nSource: KalVista Pharmaceuticals, Inc.","length":4017,"tagName":"div"}]